https://www.selleckchem.com/pr....oducts/atuzabrutinib
Treatment with Omnitrope was discontinued following diagnosis of malignancy in 16 patients. The tumors occurred after a mean of 79.4 months of recombinant hormone GH (rhGH) treatment overall. Based on this snapshot of data from PATRO Adults, Omnitrope treatment is tolerated in adult patients with GH deficiency in a real-life clinical practice setting. Our results do not generally support a carcinogenic effect of rhGH in adults with GH deficiency, although an increased risk of second new malignancies in patients with previous cance
Like
Comment
Share
